These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 20380506)

  • 1. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice.
    Schutter U; Grunert S; Meyer C; Schmidt T; Nolte T
    Curr Med Res Opin; 2010 Jun; 26(6):1377-87. PubMed ID: 20380506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study.
    Hermanns K; Junker U; Nolte T
    Expert Opin Pharmacother; 2012 Feb; 13(3):299-311. PubMed ID: 22224497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain.
    Vondrackova D; Leyendecker P; Meissner W; Hopp M; Szombati I; Hermanns K; Ruckes C; Weber S; Grothe B; Fleischer W; Reimer K
    J Pain; 2008 Dec; 9(12):1144-54. PubMed ID: 18708300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation.
    Meissner W; Leyendecker P; Mueller-Lissner S; Nadstawek J; Hopp M; Ruckes C; Wirz S; Fleischer W; Reimer K
    Eur J Pain; 2009 Jan; 13(1):56-64. PubMed ID: 18762438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged-release oxycodone/naloxone in nonmalignant pain: single-center study in patients with constipation.
    Gatti A; Casali M; Lazzari M; Tufaro G; Gafforio P; Silvestri C; Marcassa C; Sabato AF
    Adv Ther; 2013 Jan; 30(1):41-59. PubMed ID: 23269562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation.
    Poelaert J; Koopmans-Klein G; Dioh A; Louis F; Gorissen M; Logé D; Van Op den Bosch J; van Megen YJ
    Clin Ther; 2015 Apr; 37(4):784-92. PubMed ID: 25757607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study.
    Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
    Eur J Pain; 2017 Oct; 21(9):1485-1494. PubMed ID: 28474460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain.
    Clemens KE; Mikus G
    Expert Opin Pharmacother; 2010 Feb; 11(2):297-310. PubMed ID: 20030568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged-Release (PR) Oxycodone/Naloxone Improves Bowel Function Compared with Oxycodone PR and Provides Effective Analgesia in Chinese Patients with Non-malignant Pain: A Randomized, Double-Blind Trial.
    Leng X; Zhang F; Yao S; Weng X; Lu K; Chen G; Huang M; Huang Y; Zeng X; Hopp M; Lu G
    Adv Ther; 2020 Mar; 37(3):1188-1202. PubMed ID: 32020565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fixed ratio (2:1) prolonged-release oxycodone/naloxone combination improves bowel function in patients with moderate-to-severe pain and opioid-induced constipation refractory to at least two classes of laxatives.
    Koopmans G; Simpson K; De Andrés J; Lux EA; Wagemans M; Van Megen Y
    Curr Med Res Opin; 2014 Nov; 30(11):2389-96. PubMed ID: 25265132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient preference with respect to QoL and reduction in opioid-induced constipation (OIC) after treatment with prolonged-release (PR) oxycodone/naloxone compared with previous analgesic therapy [PREFER study].
    van Dongen VC; Vanelderen PJ; Koopmans-Klein G; van Megen YJ; Van Zundert J; Huygen FJ
    Int J Clin Pract; 2014 Nov; 68(11):1364-75. PubMed ID: 24853258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR.
    Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
    Eur J Pain; 2017 Oct; 21(9):1528-1537. PubMed ID: 28641363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged-release oxycodone/naloxone in opioid-naïve patients - subgroup analysis of a prospective observational study.
    Hesselbarth S; Hermanns K; Oepen P
    Expert Opin Pharmacother; 2015 Mar; 16(4):457-64. PubMed ID: 25612469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain.
    Simpson K; Leyendecker P; Hopp M; Müller-Lissner S; Löwenstein O; De Andrés J; Troy Ferrarons J; Bosse B; Krain B; Nichols T; Kremers W; Reimer K
    Curr Med Res Opin; 2008 Dec; 24(12):3503-12. PubMed ID: 19032132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial.
    Löwenstein O; Leyendecker P; Hopp M; Schutter U; Rogers PD; Uhl R; Bond S; Kremers W; Nichols T; Krain B; Reimer K
    Expert Opin Pharmacother; 2009 Mar; 10(4):531-43. PubMed ID: 19243306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations.
    Ueberall MA; Mueller-Schwefe GH
    Curr Med Res Opin; 2015; 31(7):1413-29. PubMed ID: 25942606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain.
    Sandner-Kiesling A; Leyendecker P; Hopp M; Tarau L; Lejcko J; Meissner W; Sevcik P; Hakl M; Hrib R; Uhl R; Dürr H; Reimer K
    Int J Clin Pract; 2010 May; 64(6):763-74. PubMed ID: 20370845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to low-dose oral prolonged-release oxycodone/naloxone from WHO-Step I drugs in elderly patients with chronic pain at high risk of early opioid discontinuation.
    Lazzari M; Marcassa C; Natoli S; Carpenedo R; Caldarulo C; Silvi MB; Dauri M
    Clin Interv Aging; 2016; 11():641-9. PubMed ID: 27257377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson's disease patients with chronic pain.
    Madeo G; Schirinzi T; Natoli S; Pierantozzi M; Stefani A; Dauri M; Pisani A
    J Neurol; 2015 Sep; 262(9):2164-70. PubMed ID: 26134157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer.
    Clemens KE; Quednau I; Klaschik E
    Int J Clin Pract; 2011 Apr; 65(4):472-8. PubMed ID: 21401835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.